Old Web
English
Sign In
Acemap
>
authorDetail
>
Du Lam
Du Lam
Novartis
Medicine
Internal medicine
Protein kinase A
ULK1
PI3K/AKT/mTOR pathway
4
Papers
158
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD)
2021
Blood
Matthew M. Heeney
David C. Rees
Mariane de Montalembert
Isaac Odame
R. Clark Brown
Yasser Wali
Thu Thuy Nguyen
Du Lam
Nadege Pfender
Julie Kanter
Show All
Source
Cite
Save
Citations (0)
Study Design and Initial Baseline Characteristics in Solace-Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease
2020
Blood
Matthew M. Heeney
David C. Rees
Mariane de Montalembert
Isaac Odame
R. Clark Brown
Yasser Wali
Thu Thuy Nguyen
Du Lam
Raquel Merino Herranz
Julie Kanter
Show All
Source
Cite
Save
Citations (1)
Effect of Everolimus on Subependymal Nodules (SENs) and Tubers in Patients with Subependymal Giant Cell Astrocytoma (SEGA) Associated with Tuberous Sclerosis Complex (TSC): Results from the EXIST-1 Trial (P01.049)
2013
Neurology
David Neal Franz
Du Lam
Helene Cauwel
Sergiusz Jóźwiak
Show All
Source
Cite
Save
Citations (1)
Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death
2012
Proceedings of the National Academy of Sciences of the United States of America
Noor Gammoh
Du Lam
Cindy Puente
Ian G. Ganley
Paul A. Marks
Xuejun Jiang
Show All
Source
Cite
Save
Citations (156)
1